Yuhan Corporation

Abl Bio Inc.

Na Rae Lee

Eun-Jung Lee

Moo Young Song

Young Bong Park

June Hyung Lee

Ju Young Park

Ki Hong Kim

Yangsoon Lee

Hyejin Chung

Byung Hyun Choi

Kyeongsu Park

Ui-Jung Jung

Yeryoung Yong

Wonjun Son

Jong-Seo Lee

Jong Gyun Kim

Soo Yong Chung

Seul Gi Kim

Eunyoung Park

Eunsil Sung

Yeunju Kim

Youngdon Pak

Su Youn Nam

Donghoon Yeom

Se Woong Oh

Yong-Gyu Son

Jaehyun Eom

Seawon Ahn

Minji Park

Eunjung Kim

Bong-Kook Ko

YoungKwang Kim

Hyoju Choi

Eunjeong Jeong

Taewang Kim

Jun Kyung Lee

Kyu-Tae Kim

Kwang-Hoon Lee

Nakho Chang

Sunghyun Choi

Chanmoo Lee

Ho Woong Kang

Junghyeon Hong

Su Jin Ahn

Seung Yub Shin

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Anti-TIGIT antibodies and uses thereof

Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3&#x3b1; or CCL3&#x3b2; is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3&#x3b1; or CCL3&#x3b2; in the CCL3 variant.

Fusion protein comprising CCL3 variant and use thereof

Growing community of inventors

Seoul, South Korea

Na Rae Lee